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Abstract
The horizon scanning review aimed to
identify new and emerging technologies in
development that have the potential to slow or
stop disease progression and/or reverse sight
loss in people with inherited retinal diseases
(IRDs). Potential treatments were identified
using recognized horizon scanning methods.
These included a combination of online
searches using predetermined search terms,
suggestions from clinical experts and patient
and carer focus groups, and contact with
commercial developers. Twenty-nine relevant
technologies were identified. These included
9 gene therapeutic approaches, 10 medical
devices, 5 pharmacological agents, and 5
regenerative and cell therapies. A further 11
technologies were identified in very early
phases of development (typically phase I or
pre-clinical) and were included in the final
report to give a complete picture of
developments ‘on the horizon’. Clinical
experts and patient and carer focus groups
provided helpful information and insights,
such as the availability of specialised services
for patients, the potential impacts of
individual technologies on people with IRDs
and their families, and helped to identify
additional relevant technologies. This
engagement ensured that important areas of
innovation were not missed. Most of the
health technologies identified are still at an
early stage of development and it is difficult to
estimate when treatments might be available.
Further, well designed trials that generate data
on efficacy, applicability, acceptability, and
costs of the technologies, as well as the long-
term impacts for various conditions are
required before these can be considered for
adoption into routine clinical practice.
Eye (2015) 29, 1131–1140; doi:10.1038/eye.2015.115;
published online 26 June 2015
Introduction
Inherited retinal diseases (IRDs) are a clinically
and genetically heterogeneous group of
disorders that together are an important cause of
blindness.1 There are over 100 IRDs and the
severity varies significantly.2 In England and
Wales, IRD is the commonest cause of visual
impairment registration in the working age
population and a leading cause of childhood
visual impairment.3–5 At least 4 of every 10 000
children born in the UK will be diagnosed as
severely visually impaired or blind by their first
birthday, increasing to nearly 6 per 10 000 by the
age of 16 years.5 The causes of severe visual
impairment and blindness are varied and
complex, and at least three-quarters of children
have disorders that are neither preventable nor
treatable.5 Loss of sight in addition to the impact
on the quality-of-life and emotional/
psychological well-being, also incurs significant
costs for health and social services.
There is currently no cure for IRDs and new
and more effective treatments are urgently
needed. Management is focussed on accurate
diagnosis, specialised genetic counselling,
provision of information on prognosis, and
strategies to improve the use of residual vision.
Educational and social support is also important.
Management is best provided as part of
specialised multidisciplinary services, though
the availability of such services varies
throughout the UK, with some areas having no
access at all.6 Treatment options are limited and
are focused on visual rehabilitation, including
the use of low vision aids, specialised computer
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software, orientation, and mobility training.5 The
provision of support for schooling and in the workplace is
also very important. Eye clinic liaison officers (ECLOs) are
an important source of support and provide advice on
accessing services.
In 2012, a joint priority setting exercise was facilitated
by the National Institute for Health Research (NIHR)
James Lind Alliance (JLA, www.nets.nihr.ac.uk/
identifying-research/james-lind-alliance) in a process
which brought together patients, carers, and clinicians to
identify research questions and priorities relating to sight
loss and vision.7 This partnership was initiated by the eye
research charity Fight for Sight (www.fightforsight.org.
uk). The subsequent Sight Loss and Vision Priority Setting
Partnership (PSP) report was published in October 2013,
one element of which highlighted key unanswered
questions about the recognition and management of sight
loss due to IRDs.6 Within this section, the report cites
the specific question—‘can a treatment to slow down
progression or reverse sight loss in IRDs be developed?’
as the agreed top priority for research into IRDs.
Following publication of the PSP report and discussions
with Fight for Sight, the NIHR Horizon Scanning Centre
(www.hsc.nihr.ac.uk) conducted a horizon scanning review
that sought to identify new and emerging technologies in
development that have the potential to slow or stop disease
progression and/or reverse sight loss in people with IRDs.
The NIHR Horizon Scanning Centre in conjunction with
Fight for Sight aimed to use the results of this review
to inform healthcare policy-makers, commissioners,
researchers, research funders, clinicians, and patient groups
about new therapies and advances ‘on the horizon’ that
may be of relevance to the future of IRD management.
Materials and methods
A horizon scanning review aims to identify and present
early information on all new and emerging technologies
relevant to the topic area-of-interest. A review protocol
was developed in close collaboration with Fight for Sight.
To ensure relevant technologies were captured,
treatments and therapies were included in the final
review report if they had (or claimed to have) the
potential to slow or stop disease progression and/or
reverse sight loss in people with IRDs. These included:
K Pharmacological technologies—where these were in
clinical trials with a relevant patient group and
clinically relevant patient outcomes; typically phase
II and III clinical trials.
K Medical technologies—where these were ‘emerging’
(expected to be CE marked and/or launched within
the UK within ~ 2 years), ‘new’ (CE marked and
usually only available for clinical use for less than one
year), in the launch or early post-marketing stages, or
‘new and poorly adopted’ (that is, technologies within
2 years of launch and available in only two or three
UK National Health Service (NHS) centres).
Identification of technologies
Between November 2013 and January 2014, potential
treatments were identified using recognized horizon
scanning methods.8 These included a combination of online
searches (Table 1) using predetermined search terms
(Table 2), suggestions from clinical experts, and patient and
carer focus groups, and direct contact with commercial
developers known to be active in this field. For technologies
in development or in the early phases of adoption, it is
common for there to be a lack of publicly accessible
information and scientific data available; this is particularly
true for non-pharmaceutical technologies. Where this was
the case, further information about the technology was
requested from the developers. This involved contacting
commercial developers or research institutions directly
using a standard information proforma. If no contact with
the developer could be established, a focused internet
search was conducted on the individual technology to
obtain any information available.
External input
Ten clinical experts were identified, either through our
initial scoping and literature searches, or proposed by
Fight for Sight. The experts were contacted to ask whether
they would act as review advisors, four of whom
subsequently agreed. Experts were asked to provide
information on new and emerging technologies already
known to them and to provide comments on an initial
list of relevant technologies identified, focusing on:
innovativeness; potential for impact and acceptability;
current availability and use within the UK NHS; and
potential barriers to adoption.
Fight for Sight arranged and facilitated two patient and
carer focus group discussions during which comments
were sought on the potential impact on patients and
acceptability of the identified technologies. The focus
groups were held in March 2014 and were facilitated by a
representative from the NIHR JLA and Fight for Sight.
A representative from the NIHR Biomedical Research
Centre at Moorfield’s Eye Hospital took contemp-
oraneous meeting notes. In total, 10 people attended;
5 men and 5 women; 60% were adults affected by IRDs
(all aged over 40); 40% were parents of children (aged
between 4 and 15 years) with IRDs; conditions
experienced by the participants included retinitis
pigmentosa, Leber congenital amaurosis, Stargardt
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macular dystrophy, and Usher syndrome. Of the children
represented by their parents, one was blind, one severely
visually impaired, and two at early stages of sight loss. Of
the adult patients, two were totally blind, three visually
impaired, and one still had good vision.
Review output
Technologies identified as in active development at the
time of the review were included in the report;
technologies no longer in development were excluded.
The resulting output was a descriptive list of new and
emerging technologies with the potential to slow or stop
disease progression and/or reverse sight loss. No analysis
of trial data or results obtained during the identification
stages was carried out. The review advisors and
representatives from Fight for Sight were also asked to
review the finalized report prior to publication to ensure
that the information included was accurate and that their
comments and views were represented correctly.
Results
Twenty-nine new and emerging technologies were
identified that had, or claim to have, the potential to slow
or stop disease progression and/or reverse sight loss
(Table 3). These included 9 gene therapeutic approaches,
10 medical devices, 5 pharmacological agents (drugs), and
Table 1 Search protocol—identification sources
Source name Website
Clinical trial and research registers
ClinicalTrials.gov http://www.clinicaltrials.gov
Current Controlled Trials http://www.controlled-trials.com/mrct/
EU Clinical Trials Register https://www.clinicaltrialsregister.eu/
NIHR Research Register http://www.nihr.ac.uk/databases/Pages/default.aspx
WHO International Clinical Trials Registry http://www.who.int/trialsearch/Default.aspx
Media and industry news
Clinica MedTech Intelligence http://www.clinica.co.uk/
MedGadget http://www.medgadget.com/
MEDICA http://www.medica.de/
Medical News Today http://www.medicalnewstoday.com/
Primary research and online libraries
Google Scholar http://scholar.google.com/
Medline, Medline in Progress and EMBASE http://www.elibrary.bham.ac.uk/
PubMed.gov http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
ZETOC British Library Database http://zetoc.mimas.ac.uk/
Specialist sources
EuroStemCell http://www.eurostemcell.org/
London Project to Cure Blindness www.thelondonproject.org
Moorfields Eye Hospital Trust http://www.moorfields.nhs.uk/Home
NIHR Rare Diseases Translational Research Collaboration https://www.gov.uk/government/publications/rare-diseases-
strategy
Retina Journal http://journals.lww.com/retinajournal/Pages/default.aspx
The European Blind Union http://www.euroblind.org
Technology-based sources
Adis Insight http://bi.adisinsight.com/
Pharmaprojects NA—subscription based source
NIHR Horizon Scanning Centre http://www.hsc.nihr.ac.uk/
Tertiary sources, horizon scanning and health technology assessment (HTA) agencies
Australian Safety and Efficacy Register of New Interventional
Procedures
http://www.surgeons.org
Canadian Agency for Drugs and Technologies in Health http://www.cadth.ca
ECRI Institute http://www.ecri.org
EuroScan International Network http://www.euroscan.org.uk
Health Policy Advisory Committee on Technology http://www.health.qld.gov.au/healthpact/html
International Network of Agencies for Health Technology
Assessment
http://www.inahta.org/HTA/Database/
NIHR Evaluation, Trials and Studies Coordinating Centre www.netscc.ac.uk
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5 regenerative and cell therapies. A further 11
technologies (Table 4) were identified in very early phases
of development (typically phase I or pre-clinical) and
were included in the final report to give a complete
picture of developments ‘on the horizon’. The vast
majority of technologies identified are being developed by
commercial developers, often collaborating with research
groups within universities or other research institutions.
We did not identify any one particular developer or
group prominent in this area, although some commercial
developers were developing more than one technology.
The majority of the technologies identified are in, or
anticipated to be entering, clinical trials. The most
advanced in terms of clinical trial phase are gene transfer
AAV2-hRPE65v2 (technology 2) and Rescula (isopropyl
unoprostone; Sucampo, Bethesda, MD, USA) eye drops
(technology 23), which are both in phase III trials;
Renexus (Neurotech USA, Cumberland, RI, USA;
NT-501) implant (technology 25) has completed a phase
II/III trial with reported outcomes; and human
embryonic stem cell (hESC) derived retinal pigment
epithelium (RPE) cells (technology 26) is currently in a
phase II/III trial. Three medical devices: Alpha IMS
Implant (Retina Implant AG, Reutlingen, Germany),
ARGUS II (Second Sight, Sylmar, CA, USA) and OkuStim
(Okuvision GmbH, Reutlingen, Germany; technologies
10, 11, and 17) are CE marked and available in the UK,
although not widely diffused.
Specific IRDs for which treatments are being developed
are shown in Table 5. Retinitis pigmentosa, the commonest
IRD, is the focus of developments across all technology
groups. Some technologies are in development for more
than one condition (technologies 21,22,25,27, and 29).
Expert input
Clinical experts provided comment on 30 of the 40
technologies. Experts were able to provide more detailed
comments on technologies more advanced in terms of
trial phase. They were able to give useful insights into the
potential impact of the technology, trial status, and
probable timeframe for the technology.
Gene-based therapies were thought to have potential to
improve retinal function or slow retinal degeneration, but
clinical trials of these technologies are at an early stage and
longer term follow-up is needed to determine whether the
treatment is effective. The trials for gene replacement
therapy for retinal disease caused by mutations in RPE65
have demonstrated that gene replacement therapy is safe
and can improve retinal function, but may not prevent
progressive retinal degeneration.9–11 One expert
commented that the uptake in the NHS will be a key step if
gene therapy is going to impact on patients with pressure
for patients to be referred to major specialist centres.
Experts questioned whether these technologies would
meet the National Institute for Health and Care Excellence
(NICE) cost-utility criteria.
Overall, there was less input on medical technologies.
Two experts preferred to comment on medical
technologies as a group rather than as individual
technologies. Experts had mixed views on the Okustim
System (technology 17). One expert thought it had little
scientific basis, whereas another thought it was
innovative and cutting edge. Both agreed that more
results from clinical trials were needed. There were
doubts from experts whether the Smart-Glasses (Assisted
Vision, Oxford Smart Specs, Oxford, UK; technology 19)
would be used regularly and it was thought that the
PRIMA (Micro Photovoltaic Retinal Implant Array)
implant (technology 18) needed further results before it
could be determined if it would work.
Experts provided views on the individual
pharmacological technologies in development. There was
a question on the efficacy of brimonidine (technology 20)
considering that when given topically there is no evidence
that it has a protective effect in retinitis pigmentosa. It
was commented that work in mouse models suggest that
inhibitors of the visual cycle such as fenretinide
Table 2 Search terms
Mesh headings
Eye diseases, hereditary; retinal diseases
Inherited retinal diseases
Achromatopsia
Adult vitelliform macular dystrophy
Alström syndrome
Bardet–Biedl syndrome
Best disease
Choroideremia
Cone dystrophies
Fundus flavimaculatus
Juvenile macular dystrophy
Leber congenital amaurosis
Retinal dystrophy
Retinitis pigmentosa (RP)
Sorsby macular dystrophy
Stargardt disease/macular dystrophy
Usher syndrome
Technology type
Advanced (regenerative) therapies
Gene therapy
Medical device
Medical technology (medtech)
Pharmaceuticals/drugs
Purpose
Slow/stop disease progression
Reverse sight loss
Restore sight/vision
Timeframe
New
Emerging
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Table 3 Review findings
Technology name Patient group Developer Stage of development
eg, clinical trial phase
Gene therapy
Gene Therapy AAV.REP1 Choroideremia Nightstar Phase I/II
Gene transfer AAV2-hRPE65v2 Leber congenital amaurosis
(LCA2)
Spark Therapeutics Phase III
Gene Therapy AAV2/2-
hRPE65p-hRPE65
Leber congenital amaurosis The University College London,
Moorfields Eye Hospital, AmpliPhi
Biosciences (formerly Targeted Genetics)
Phase I/II
Gene therapy rAAV2-CB-hRPE65
Leber congenital amaurosis Applied Genetic Technologies Corp Phase I/II
Gene therapy (RPE65 mutation)
Leber congenital amaurosis The Nantes University Hospital Phase I/II
Gene therapy rAAV2-CBSB-
hRPE65
Leber congenital amaurosis The University of Pennsylvania Phase I/II
Gene therapy rAAV2-VMD2-
hMERTK
Retinitis pigmentosa (due to
MERTK mutations)
King Khaled Eye Specialist Hospital Phase I/II
Gene replacement–UshStat;
StarGen; MY07A
Retinitis pigmentosa
associated with Usher
Syndrome Type 1B
Sanofi, Oxford BioMedica Phase I/II
StarGen using LentiVector
technology to deliver a healthy
copy of the ABCR gene
Stargardt macular dystrophy Sanofi, Oxford BioMedica Phase I/II
Medical technologies
Alpha IMS implant Retinitis pigmentosa Retina Implant AG CE marked and
available; subject to
ongoing phase I/II trial
ARGUS II Retinal Prosthesis
System
Retinitis pigmentosa Second Sight CE marked and
available
High-Acuity device Retinitis pigmentosa Bionic Vision Not yet CE marked
Wide-View device Retinitis pigmentosa Bionic Vision Not yet CE marked
Bionic Eye Technologies
Retinal Prosthesis
Retinitis pigmentosa The Boston Retinal Implant Project Clinical study planned
starting in 2014
Image Processing Retinal
Implant System (EPI-RET Project)
Retinitis pigmentosa University of Bonn, Intelligent Implants
GmbH
In clinical trials
IRIS2 System Retinitis pigmentosa Pixium Vision S.A. Patient testing in 2014,
and CE mark expected
during 2015
Okustim System –Transcorneal
Electrical Stimulation (TES)
Retinitis pigmentosa Okuvision GmbH CE marked and
available for research
use in the UK
PRIMA (Micro Photovoltaic
Retinal Implant Array)
Retinitis pigmentosa Pixium Vision S.A. with Stanford
University
In clinical trials
Smart-Glasses (depth based
visual aid); Oxford Smart Specs
Impaired vision Assisted Vision, Oxford Smart Specs
Research Group
Patient testing ongoing
Pharmacological technologies
Brimonidine Intravitreal
Implant
Retinitis pigmentosa Pfizer (originator); Allergan (licensee) Phase I/II
Fenretinide (RT-101)–inhibitor
of vitamin A delivery to RPE
Dry age-related macular
degeneration (AMD);
Stargardt macular dystrophy
ReVision Therapeutics Phase II
QLT091001 (oral); synthetic
retinaldehyde
Leber congenital amaurosis
(LCA) or RP due to RPE65 or
LRAT deficiency
QLT Phase I/II
Rescula (isopropyl
unoprostone); Ocuseva
eye drops
Retinitis pigmentosa Sucampo Pharma Europe Ltd, RTech Ueno
Ltd
Phase III
Valproic Acid (VPA); oral Retinitis pigmentosa Foundation Fighting Blindness Clinical
Research Institute
Phase II
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(technology 21) may be of value in Stargardt macular
dystrophy. There was a view that isopropyl unoprostone
(technology 23) may not show an effect in trials, as trials
of neurprotective agents are difficult to do because of
patient numbers and the long-term follow-up required.
The phase II trial of valproic acid (technology 24) was said
to be based on limited animal work. The expert was
pessimistic about the outcome.
Regenerative and cellular therapies identified in phase
II/III clinical trials were Renexus (NT-501) (technology
25) and hESC-derived RPE cells (technology 26). Expert
opinion was that Renexus would be unlikely to be
developed as a treatment due to disappointing trial
results. There were also doubts about hESC-derived RPE
cells for Stargardt macular dystrophy. A safety study has
demonstrated it to be safe in the short term, but the expert
doubted the clinical effectiveness, as the vast majority of
patients with Stargardt macular dystrophy who may
benefit from stem cell therapy need replacement of both
RPE cells and photoreceptors and this technology only
replaces RPE cells. The other regenerative technologies
were in phase I/II trials. Although the expert commented
that ‘cell replacement therapy holds out great hope’, this
was accompanied with a cautious note that ‘much more
pre-clinical work in animal models is needed’.
Table 3. (Continued )
Technology name Patient group Developer Stage of development
eg, clinical trial phase
Regenerative and cell therapies
Renexus NT-501 ciliary
neurotrophic factor (CNTF)
implant
Retinitis pigmentosa (early
and late stage); Usher
Syndrome; choroideremia
Neurotech USA, Inc. Completed phase II/III
trial and reported
outcomes
Human embryonic stem cell
derived retinal pigment
epithelium (RPE) cells
Stargardt macular dystrophy Advanced Cell Technology Phase II/III
Human embryonic stem cell
derived retinal pigment
epithelium (RPE) cells
Retinitis pigmentosa; AMD London Project to Cure Blindness, IRIS
UCL in collaboration with Pfizer
Clinical trial is planned
ReN003 programme (stem cell) Retinitis pigmentosa ReNeuron Phase I/II
Stem Cell Ophthalmology
Treatment Study (SCOTS)
Retinal diseases (and optic
nerve); macular degeneration
Retinal Associates of South Florida Phase I/II
Table 4 Technologies identified in the very early stages of development
Technology name Patient group Developer Stage of development
eg, clinical trial phase
ACU-4429; Emixustat
Hydrochloride
AMD; therapeutic potential for
Stargardt macular dystrophy
Acucela In trials for AMD at
present
ALK-001 Therapeutic potential for Stargardt
macular dystrophy
Alkeus Pharmaceuticals Phase I
Altered form of vitamin A Stargardt macular dystrophy Columbia's Harkness Eye Institute Pre-clinical
Engineered virus for gene
therapy delivery
Retinitis pigmentosa The University of California at Berkeley Pre-clinical
Glial cell and retinal
progenitor cells in retina
repair
Retinal diseases The University of Washington Pre-clinical
Nanoparticle gene therapy Retinitis pigmentosa Department of Cell Biology, The University of
Oklahoma Health Sciences Center
Pre-clinical
NS2 eye drop Therapeutic potential for Stargardt
macular dystrophy
Aldexa Completed Phase I
trial
Optogenetic therapy Retinitis pigmentosa NA Pre-clinical
Photoreceptor
transplantation–embryonic
stem cells
Retinal diseases The UCL Institute of Ophthalmology and
Moorfields Eye Hospital
Pre-clinical
Piezoelectric inkjet (or ‘3D’)
printer
Glaucoma (currently) The University of Cambridge Pre-clinical; proof-
of-principle
VSM 20R Therapeutic potential for Stargardt
macular dystrophy
Visium Pre-clinical
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Some of the technologies in earlier development were
thought by the experts to have a good scientific basis, but
need to be assessed in clinical trials (technologies 30, 31,
and 36).
Patient and carer focus group input
The focus groups commented on seven of the technologies.
They thought that the Alpha IMS implant (technology 10)
was an innovative and interesting development. The
Okustim System (technology 17) stood out to some as it is
believed to be already available and improves function,
but currently has to be paid for. Others thought it sounded
‘nice and simple’, so were attracted to it, assuming it gives
good improvement to sight. The groups were unsure
whether they would want to wear video gaming goggles
in public (PRIMA, Pixium Vision, Paris, France;
technology 18). There was some excitement for NT-501
(technology 25) as a development and the fact that it is a
later phase of development than some technologies.
However, there was some concern that another
regenerative technology ReN003 (ReNeuron, Guildford,
Surrey, UK; technology 28) uses non-embryonic tissue. It
was felt that this may limit its use and that more could be
done if embryos had been the source of stem cells.
Discussion
Currently, there is no cure or specific treatment for IRDs.
However, a number of commercial developers and
academic research groups are presently working on
multiple avenues of intervention, including correcting the
underlying defect, regenerating damaged retinal cells,
preventing further retinal deterioration, providing artificial
methods of sensing light, or improving assistive
technologies. Some of these are in early clinical trials.
Experts indicate that some of these developments are more
applicable to the earlier stages of disease before significant
retinal deterioration, such as gene therapy, while others are
more applicable to advanced stages of the disease, such as
artificial vision and stem cell therapy. These treatments are
not mutually exclusive and may be complementary,
potentially used either together or sequentially.
Many of these identified technologies are invasive
treatments that involve subretinal injections, implants, and
associated procedures (often involving complex surgery).
There are risks generally associated with these treatments
such as infection, damage to local structures, and
inflammation, all of which have the potential to worsen
any remaining vision. The patient and carer focus groups
commented that people who had not yet lost their sight
would be keen to have detailed information about the
possible risks and complications for each new treatment so
they can decide whether the potential benefits are worth it.
They indicated that any remaining vision is precious so
they would not want to do anything that risked damage
and further loss of vision. However, most treatments in
development will be offered to only one eye, usually the
worst affected, and as the disease is symmetrical in most
genetic eye disease the risk to sight loss is to some extent
ameliorated. Note that an exception to this is the current
phase III of gene transfer AAV2-hRPE65v2 (technology 2),
where the technology is being used to treat both eyes.
Developments in medical technologies
Most of the developments in medical technology are
implants that sit either on the retinal surface (technologies
11, 15, and 16) or underneath the retina (technologies 10
and 14), with some using an external camera on a
spectacle frame linked to the implant to enable vision
(for example, ARGUS II, technology 11), while another
incorporates light-sensitive photodiodes (Alpha IMS,
technology 10). There are two technologies CE marked
and commercially available: the ARGUS II and the Alpha
IMS. The focus groups commented that the appearance of
technologies was important to younger people in
particular. They suggested that appearance should be part
of any technology design from the start. One woman said
that even carrying a white stick had been a ‘barrier to
cross’ as it made her feel noticeably different from other
people. The patient focus groups suggested that even
where a technology is effective, if people do not wish to
wear the new device because of its appearance it will
never be fully adopted. For example, some doubts were
expressed over whether the PRIMA (technology 18)
would be practical and acceptable as it means wearing
‘gaming’ style goggles.
Table 5 Specific IRDs subject to clinical trials
Technology group IRDs in clinical trials
Gene therapy Choroideremia
Leber congenital amaurosis
Retinitis pigmentosa (RP) due to
MERTK mutations
RP associated with Usher Syndrome
Type 1B
Stargardt macular dystrophy
Medical technology Retinitis pigmentosa
Pharmacological Leber Congenital Amaurosis
Retinitis pigmentosa
RP due to RPE65 or LRAT deficiency
Stargardt macular dystrophy
(therapeutic potential)
Regenerative and cell
therapy
Choroideremia
Retinitis pigmentosa
Stargardt macular dystrophy
Usher Syndrome
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Clinical experts commented that most of the devices
identified are for patients with advanced and end stage
disease—patients who have lost the majority of their
photoreceptors and have minimal vision. What these devices
rely on is the observation that nerve fibres of the retina are
still intact and can be stimulated directly to give some form
of vision. Users need training and support to help them to
interpret the information transmitted to the visual cortex,
which needs to be allowed for in planning services. These
devices are not suitable for people with severe infantile onset
retinal dystrophies who have never had sight. In addition,
there remain some unanswered questions, including long-
term biocompatibility (for example, conjunctival erosion,
retinal detachments, increased intraocular pressure, and
decreased retinal perfusion) and the long-term effects of
chronic nerve fibre stimulation.
Pharmacological developments
The most advanced drug in development is Rescula
(isopropyl unoprostone) eye drops (technology 23), which
is currently in a phase III clinical trial. Of the five drugs
in phase II or phase III development, three are in
development for retinitis pigmentosa. On the more
distant horizon, there are also multiple drugs in
pre-clinical or phase I development for slowing/halting
progression of Stargardt macular dystrophy (Table 4).
Gene and regenerative therapies
Clinical expert and patient opinion indicates that the
technologies likely to have the most impact in the future
are gene therapies, and regenerative and cell therapies.
Gene therapy is more advanced in terms of clinical
development and has the potential to slow retinal
degeneration or improve retinal function. The retina, as a
gene therapy target, has features that facilitate therapeutic
interventions.12 There is good surgical access and the
route of administration can be altered to enable targeting
of either the inner retina (by intravitreal injection), or the
outer retina and RPE, by subretinal injection.12 The
blood–retina barrier separates the subretinal space from
the blood supply, enhancing the prospects for effective
gene therapy by relative protection from immune-
mediated damage.12 Current research is focusing on
optimizing the adeno-associated virus (AAV) delivery
vector to enhance gene expression (technologies 1–7),
allow larger genes to be delivered, and increasing chances
of the treatment successfully targeting either RPE or
photoreceptor cells.13 Lentiviral vectors are also being
investigated (technologies 8 and 9) and is the vector being
used in clinical trials of gene therapy for retinitis
pigmentosa associated with Usher syndrome Type 1B and
Stargardt macular dystrophy.12
Gene therapy has the potential for long-term efficacy
following a single administration of a vector that could
be much more cost effective than repeated drug
administrations. The vast majority of IRDs result from
mutations in photoreceptor-specific genes, and gene
therapy research could expand the range of retinal
disorders potentially amenable to this approach.
However, gene therapy approaches are most suitable for
treating disorders once the degenerative process has
resulted in extensive retinal cell loss. In addition, there are
retinal disorders that are not currently suitable for gene
therapy. In later stage disease, visual loss results from the
death of retinal neurons, rather than loss of function of
retinal neurons seen in earlier stages of disease.
An alternative approach is to replace lost photoreceptors/
RPE cells using cell transplantation. According to the
clinical experts, transplantation of photoreceptor cells has
shown promise in animal models.
The eye has several properties that also make it a
suitable target for regenerative approaches, such as
relative ease of access and relative isolation from other
body systems.14 Stem cells have the ability to self renew,
the capacity to differentiate into other more specialised
cells and the potential to replace damaged or missing
retinal cells. Studies suggest that stem cells have the
capacity to regenerate lost photoreceptors and improve
vision.15 The techniques used at present are still
relatively new, but their applications and benefits may
be broad in the future. Stem cell therapies are generally
considered safe. However, a patient’s immune system
may recognize the transplanted cells as foreign and this
can trigger an immune reaction that results in rejection of
the new cells. Genetic techniques have continued to
advance and new gene editing technologies may allow
the gene defect to be corrected in the patient’s own cells
before being transplanted.16 This will avoid an
immunological reaction as the patient’s own cells will be
used. There are also potential concerns regarding
tumour formation and longer term human studies are
needed to assess the true safety profile of such
treatments. In addition, there are ethical concerns
associated with the use of embryonic stem cells in
research, which will need addressing before widespread
implementation by health services.17
This review identified five regenerative and cell
therapies. The most advanced of these in terms of clinical
trials is Renexus (NT-501, technology 25). This consists of
encapsulated human cells genetically modified to secrete
ciliary neutrophic factor (CNTF), a growth factor that
stimulates and protects neural cells. According to
company information, Renexus is designed to continually
deliver a safe and therapeutic dose of CNTF into the site
of treatment.18 However, preliminary results in
achromatopsia and retinitis pigmentosa have been
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disappointing and the experts felt that this is unlikely to
be developed as a technology.19,20
What this review adds
This horizon scanning review summarises innovation in a
disease area that has been previously underreported and
has a significant negative impact on people’s quality-of-
life. Through working closely with Fight for Sight, the
NIHR Horizon Scanning Centre has addressed the key
question ‘can a treatment to slow down progression or
reverse sight loss in IRDs be developed?’ cited in the Sight
Loss and Vision PSP report. Identifying these technologies
helps focus research funding on those developments that
are showing promise, identifies gaps in research for some
diseases that do not appear to be attracting attention, and
introduces policy-makers to changes to service provision
that may be required in the future. Fight for Sight have
indicated they have used the horizon scanning review
findings: to ‘raise the profile for eye research to attract
more funding into the arena’ and alongside the JLA PSP
‘to engage with the key funders of eye research to identify
the gaps in research and where investment is needed’.
The incorporation of both clinical expert and patient
views offers a rich perspective to horizon scanning
reviews. Clinical experts, and patient and carer focus
groups assisted with the review and provided a wide
range of helpful information and insights, such as the
availability of specialised services for patients, the
potential impacts (positive and negative) of individual
technologies on people with IRDs and their families, and
helped to identify additional relevant technologies
(particularly those in earlier phases of development). This
engagement ensured that important areas of innovation
were not missed. The focus groups in particular provided
valuable insights into the technologies presented from
potential user’s perspective; however, the comments
highlighted the hope that patients hold for some
technology developments that may be still some way
off or less likely to succeed. The focus groups also
highlighted a number of concerns related to the future
access to new treatments including:
K Many people with IRDs have been discharged from
NHS care as they have conditions which are currently
incurable and their management is focused on visual
rehabilitation, support, and training delivered in
community settings. This could make it difficult for
these people to gain access to new treatments.
K There should be more attention paid to informing
clinicians about new developments as and when they
become available. There is some concern about
availability of treatments/clinical trials being
dependent on the awareness of the individual con-
sultant and some people find it difficult to challenge
their doctors to gain access to new treatments. At
present, patients feel the onus is largely on them to
find out about emerging treatments. ECLOs, patient
groups, and charities should be made aware of newly
available treatments as they become available on the
NHS, so they can share the information more widely.
K There is a particular need for outreach workers to
ensure that those of different cultures and ethnicities
are included in developments and opportunities,
especially for those conditions which are more
prevalent in defined ethnic groups.
K New therapies and devices are likely to be expensive,
and patients expressed concerns that novel treatments
will only be made available to younger people,
potentially ignoring the needs of older people.
K The ‘hype’ in the media about specific treatments can
give false hope to people. For example, when a
newspaper prints a story, people want to be part of a
trial even though the research is at an early stage,
often a long way from patient recruitment stage.
Although this is a time of unprecedented innovation for
developing potential therapies for IRDs, most of the
health technologies identified in this review are still at an
early stage of development and it is difficult to estimate
when treatments might be available in the clinic. Further,
well designed trials that generate data on efficacy,
applicability, acceptability, and costs of the technologies,
as well as the long-term impacts for various conditions
are required before these can be considered for adoption
into routine clinical practice.
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